ESMO TAT 2023 | Predicative biomarkers in prostate cancer

Pasquale Rescigno, MD, PhD, Newcastle University, Newcastle, UK, provides an overview of current and upcoming predicative biomarkers in prostate cancer, including PD-L1, TIGIT, and LAG3. B7-H3 has been identified as an emerging biomarker, where it is highly expressed in prostate cancer. This interview took place at the ESMO Targeted Anticancer Therapies (TAT) Congress 2023 in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.